Trial Profile

26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Most Recent Episode Manic)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Oct 2022 Results assessing longer-term effectiveness, safety, and tolerability of open-label ziprasidone in children and adolescents with bipolar I disorder , published in the Journal of Child and Adolescent Psychopharmacology.
03 Sep 2020 Status changed from recruiting to discontinued. Reason the study was stopped: Pfizer has decided to perform the pre-specified final analysis at the current enrollment using a re-estimation of the sample size.
03 Aug 2020 Planned End Date changed from 7 Jul 2021 to 6 Aug 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com